scholarly journals Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Alexandra Ion ◽  
Iris Maria Popa ◽  
Laura Maria Lucia Papagheorghe ◽  
Cristina Lisievici ◽  
Mihai Lupu ◽  
...  
Keyword(s):  
T Cell ◽  
Biomarker Discovery ◽  
Skin Diseases ◽  
Cell Lymphoma ◽  
Tumor Biology ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Inflammatory Skin Diseases ◽  
Protein Marker

Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy. Although multiple biomarkers linked to CTCL have been known for a relatively long time (e.g., CD25, CD45, CD45RA, and CD45R0), compared to other cancers (lymphoma, melanoma, colon carcinoma, head and neck cancer, renal cancer, and cutaneous B-cell lymphoma), information about the antigenicity of CTCL remains relatively limited and no dependable protein marker for CTCL has been discovered. Considering the aggressive nature of some types of CTCL, it is necessary to identify circulating molecules that can help in the early diagnosis, differentiation from inflammatory skin diseases (psoriasis, nummular eczema), and aid in predicting the prognosis and evolution of this pathology. This review aims to bring together some of the information concerning protein markers linked to CTCL, in an effort to further the understanding of the convolute processes involved in this complex pathology.

scholarly journals High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma

Blood ◽  
2011 ◽  
Vol 117 (6) ◽  
pp. 1966-1976 ◽  
Author(s):  
Rachael A. Clark ◽  
Jeffrey B. Shackelton ◽  
Rei Watanabe ◽  
Adam Calarese ◽  
Kei-ichi Yamanaka ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Skin Diseases ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Inflammatory Skin Diseases ◽  
Inflammatory Skin ◽  
Malignant T Cells

Abstract In early-stage cutaneous T-cell lymphoma (CTCL), malignant T cells are confined to skin and are difficult to isolate and discriminate from benign reactive cells. We found that T cells from CTCL skin lesions contained a population of large, high-scatter, activated skin homing T cells not observed in other inflammatory skin diseases. High-scatter T (THS) cells were CD4+ in CD4+ mycosis fungoides (MF), CD8+ in CD8+ MF, and contained only clonal T cells in patients with identifiable malignant Vβ clones. THS cells were present in the blood of patients with leukemic CTCL, absent in patients without blood involvement, and contained only clonal malignant T cells. The presence of clonal THS cells correlated with skin disease in patients followed longitudinally. Clonal THS cells underwent apoptosis in patients clearing on extracorporeal photopheresis but persisted in nonresponsive patients. Benign clonal T-cell proliferations mapped to the normal low-scatter T-cell population. Thus, the malignant T cells in both MF and leukemic CTCL can be conclusively identified by a unique scatter profile. This observation will allow selective study of malignant T cells, can be used to discriminate patients with MF from patients with other inflammatory skin diseases, to detect peripheral blood involvement, and to monitor responses to therapy.

scholarly journals Coexistent B-cell Lymphoma and Cutaneous T-cell Lymphoma

2006 ◽  
Vol 45 (9) ◽  
pp. 641-647 ◽  
Author(s):  
Taku Inokuchi ◽  
Mayumi Shincho ◽  
Yuji Moriwaki ◽  
Tsuneyoshi Ka ◽  
Sumio Takahashi ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma

scholarly journals A Rare Case of Cutaneous T-Cell Lymphoma Accompanied by Acute Monoblastic Leukemia and Diffuse Large B-Cell Lymphoma

2021 ◽  
Vol 33 (2) ◽  
pp. 178
Author(s):  
Eun Hye Hong ◽  
Ye Ji Jang ◽  
Eun Byul Cho ◽  
Eun Joo Park ◽  
Kwang Joong Kim ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Acute Monoblastic Leukemia ◽  
Large B Cell

scholarly journals Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Anna Vasku ◽  
Julie Bienertova Vasku ◽  
Miroslav Nečas ◽  
Vladimir Vasku
Keyword(s):  
T Cell ◽  
Skin Diseases ◽  
Cell Lymphoma ◽  
Early Stage ◽  
Clinical Diagnostics ◽  
T Cell Lymphoma ◽  
Matrix Metalloproteinase 2 ◽  
Potential Candidate ◽  
Cutaneous T Cell Lymphoma ◽  
History Of

The aim of the study was to investigate the DNA polymorphic genotype in MMP-2 promoter gene as a potential candidate region for the development of the cutaneous T-cell lymphoma (CTCL) and/or its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls of similar age and sex distribution, without personal or family history of chronic skin diseases and without personal history of malignancy. The three selected polymorphisms in the promoter of MMP-2 gene (−1575G/A,−1306C/T, and−790T/G) were determined using the PCR-based methodology with RFLP. In our cohort, the associatedGGCCTTMMP-2 promoter genotype was highly significantly more frequent in CTCL-Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP-2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in the early stages.

Diffuse large B-cell lymphoma developing in erythrodermic cutaneous T-cell lymphoma: a case series

2017 ◽  
Vol 177 (4) ◽  
pp. e138-e140 ◽  
Author(s):  
B.C.Y. Chan ◽  
C.M. Stefanato ◽  
M.T. Moonim ◽  
S.L. Morris ◽  
P. Fields ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
Case Series ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Methotrexate-induced Primary Cutaneous Diffuse Large B-cell Lymphoma in Patients with Erythrodermic Cutaneous T-cell Lymphoma

2020 ◽  
Vol 100 (15) ◽  
pp. adv00226
Author(s):  
J Delaleu ◽  
E Maubec ◽  
F Rodrigues ◽  
A Lévy ◽  
V Szablewski ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

Blood ◽  
2011 ◽  
Vol 118 (22) ◽  
pp. 5891-5900 ◽  
Author(s):  
Ulrik Ralfkiaer ◽  
Peter H. Hagedorn ◽  
Nannie Bangsgaard ◽  
Marianne B. Løvendorf ◽  
Charlotte B. Ahler ◽  
...  
Keyword(s):  
T Cell ◽  
Skin Diseases ◽  
Cell Lymphoma ◽  
Independent Set ◽  
High Specificity ◽  
T Cell Lymphoma ◽  
Pcr Analysis ◽  
Inflammatory Skin Diseases ◽  
Diagnostic Potential ◽  
Specificity And Sensitivity

AbstractCutaneous T-cell lymphomas (CTCLs) are the most frequent primary skin lymphomas. Nevertheless, diagnosis of early disease has proven difficult because of a clinical and histologic resemblance to benign inflammatory skin diseases. To address whether microRNA (miRNA) profiling can discriminate CTCL from benign inflammation, we studied miRNA expression levels in 198 patients with CTCL, peripheral T-cell lymphoma (PTL), and benign skin diseases (psoriasis and dermatitis). Using microarrays, we show that the most induced (miR-326, miR-663b, and miR-711) and repressed (miR-203 and miR-205) miRNAs distinguish CTCL from benign skin diseases with > 90% accuracy in a training set of 90 samples and a test set of 58 blinded samples. These miRNAs also distinguish malignant and benign lesions in an independent set of 50 patients with PTL and skin inflammation and in experimental human xenograft mouse models of psoriasis and CTCL. Quantitative (q)RT-PCR analysis of 103 patients with CTCL and benign skin disorders validates differential expression of 4 of the 5 miRNAs and confirms previous reports on miR-155 in CTCL. A qRT-PCR–based classifier consisting of miR-155, miR-203, and miR-205 distinguishes CTCL from benign disorders with high specificity and sensitivity, and with a classification accuracy of 95%, indicating that miRNAs have a high diagnostic potential in CTCL.

Sign in / Sign up

Export Citation Format

Share Document